Incyte Corporation vs Travere Therapeutics, Inc.: Annual Revenue Growth Compared

Biotech Giants: Incyte vs Travere Revenue Growth Battle

__timestampIncyte CorporationTravere Therapeutics, Inc.
Wednesday, January 1, 201451149500028203205
Thursday, January 1, 201575375100099892000
Friday, January 1, 20161105719000133591000
Sunday, January 1, 20171536216000154937000
Monday, January 1, 20181881883000164246000
Tuesday, January 1, 20192158759000175338000
Wednesday, January 1, 20202666702000198321000
Friday, January 1, 20212986267000227490000
Saturday, January 1, 20223394635000212018000
Sunday, January 1, 20233695649000145238000
Monday, January 1, 20244241217000
Loading chart...

In pursuit of knowledge

Incyte Corporation vs Travere Therapeutics: A Decade of Revenue Growth

In the competitive landscape of biotechnology, revenue growth is a key indicator of success. Over the past decade, Incyte Corporation has demonstrated a remarkable trajectory, with its annual revenue surging by over 620% from 2014 to 2023. Starting at approximately $511 million in 2014, Incyte's revenue reached nearly $3.7 billion by 2023, showcasing its robust market presence and strategic advancements.

In contrast, Travere Therapeutics, Inc. experienced a more modest growth, with its revenue increasing by around 415% over the same period. Despite starting at a lower base of approximately $28 million in 2014, Travere's revenue peaked at about $227 million in 2021 before slightly declining in 2023.

This comparison highlights the dynamic nature of the biotech industry, where strategic innovation and market adaptation are crucial for sustained growth and competitiveness.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025